Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study

BACKGROUND: The epidermal growth factor receptor (EGFR) is over-expressed in 70–75% of colorectal adenocarcinomas (CRC). The anti-EGFR monoclonal antibody cetuximab has been approved for the treatment of metastatic CRC, however tumor response to cetuximab has not been found to be associated with EGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Razis, Evangelia, Briasoulis, Evangelos, Vrettou, Eleni, Skarlos, Dimosthenis V, Papamichael, Dimitrios, Kostopoulos, Ioannis, Samantas, Epaminontas, Xanthakis, Ioannis, Bobos, Mattheos, Galanidi, Eleni, Bai, Maria, Gikonti, Ioanna, Koukouma, Alona, Kafiri, Georgia, Papakostas, Pavlos, Kalogeras, Konstantine T, Kosmidis, Paris, Fountzilas, George
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527615/
https://www.ncbi.nlm.nih.gov/pubmed/18700047
http://dx.doi.org/10.1186/1471-2407-8-234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527615/
https://www.ncbi.nlm.nih.gov/pubmed/18700047
http://dx.doi.org/10.1186/1471-2407-8-234

Ejemplares similares